novo nordisk semaglutide copycat risk Hims & Hers Undercuts Novo's Wegovy Pill With $49 in Weight-Loss War Novo Nordisk Investors Breathe Sigh

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

DPP-4 inhibitors may be a treatment option for patients in whom metformin is contraindicated due to decreased renal function or intolerable gastrointestinal side effects

Unlike nicotinic acid (niacin), niacinamide does not have significant lipid-modifying effects and does not share the same interaction profile

Talk with your doctor about how often you should check your blood sugar

Dietary strategies during titration The first few weeks of any GLP-1 peptide protocol are the hardest from a side effect standpoint